Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00912743 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00912743 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 33 participants.
The verdict
NCT00912743, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This study is being carried out to see if the new drug, olaparib (AZD2281), can effectively and safely treat advanced large bowel cancer. The primary goal of this clinical trial is to determine whether olaparib will have a beneficial effect on the patient's cancer by causing a response and increasing the time it takes for the cancer to progress.
Interventions
- DRUG olaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00912743
The ClinicalTrials.gov registry entry for NCT00912743 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which olaparib is the first listed.
NCT00912743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00912743 about?
NCT00912743 is a clinical study titled "Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status". This study is being carried out to see if the new drug, olaparib (AZD2281), can effectively and safely treat advanced large bowel cancer. The primary goal of this clinical trial is to determine whether olaparib will have a beneficial effect on the patient's cancer by causing a response and increasin...
What is the current status of trial NCT00912743?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2009-05. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00912743?
The interventions under investigation include: olaparib (DRUG).
Who is sponsoring clinical trial NCT00912743?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.